Alnylam Pharmaceuticals faced a significant decline in its stock price following a downgrade from JPMorgan.
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) saw its stock drop by 6.31% yesterday, closing at CA$231.18. This decline was mainly due to a downgrade from JPMorgan, which adjusted its price target due to concerns about the demand for its key product, Amvuttra.
Investor takeaway: Investors should stay cautious as Alnylam deals with challenges in demand forecasts for its leading therapies, especially considering the recent analyst downgrades.
Advertisement
Alnylam Pharmaceuticals Inc
ALNY.US
ALNY.US
Alnylam Pharmaceuticals Inc
WealthAwesomeMarket cap
$33.02B
P/E
44.2x
52W high
$495.55
52W low
$197.81
1W change
-7.38%
Beta
0.30
Analyst Price Targets
Based on 30 analysts covering ALNY · as of Oct 2, 2026
Wall Street analysts forecast ALNY stock price to rise 60.5% over the next 12 months.
Consensus
Buy4.23 / 5.00
Avg. Target
C$371.12
+60.5% Upside
Previously C$371.35 on Sep 17, 2026
Current Price
C$231.18
Last close
Analyst Breakdown (30 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ALNY's historical volatility
30-Day Vol
47.3%
Annualized
90-Day Vol
76.4%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$193.37
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$217.82 | C$185.04 – C$256.41 |
| 60 trading days | C$205.23 | C$162.96 – C$258.48 |
| 90 trading days | C$193.37 | C$145.78 – C$256.50 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Bull case
Alnylam remains a leader in RNAi therapeutics, boasting a strong pipeline and innovative products that could fuel future growth if market conditions improve.
Bear case
The recent downgrade underscores potential weaknesses in demand for Amvuttra, which could affect revenue and investor confidence moving forward.
Market Reaction to Downgrade
Advertisement
Alnylam's stock fell sharply after JPMorgan cut its price target, citing worries about Amvuttra's demand. This downgrade has raised concerns among investors about the sustainability of Alnylam's revenue growth, particularly since the company relies heavily on this product for its financial performance.
Future Outlook for Alnylam
Despite the recent setback, Alnylam remains a significant player in the RNAi therapeutics space. The company's pipeline includes promising candidates that could strengthen its market position. However, current market sentiment indicates that investors will closely watch demand trends and any further analyst actions.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
